Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

Subependymal giant cell astrocytoma physical examination

Introduction

Overview

Overview

Common physical examination findings in patients with subependymal giant cell astrocytoma include hypomelanotic macules, retinal hamartomas, sensory deficits, and muscle weakness. Because subependymal giant cell astrocytoma is predominantly seen in people with tuberous sclerosis, the examination findings listed are those seen in tuberous sclerosis patients.

Physical Examination

Physical Examination

Due to the fact that subependymal giant cell astrocytoma is predominantly seen in people with tuberous sclerosis, majority of the physical examination findings are those in tuberous sclerosis patients. The common physical examination findings include:[1][2][3][4][5]

Appearance

  • Patients with subependymal giant cell astrocytoma usually appear normal.

Vital Signs

  • Vital signs of patients with subependymal giant cell astrocytoma are usually normal.

Skin

  • Hypomelanotic macules
  • Confetti skin lesions
  • Facial angiofibromas
  • Shagreen patches
  • Fibrous cephalic plaques
  • Ungual fibromas

HEENT

Neck

  • Neck examination of patients with subependymal giant cell astrocytoma is usually normal.

Lungs

  • Pulmonary examination of patients with subependymal giant cell astrocytoma is usually normal.

Heart

  • Cardiovascular examination of patients with subependymal giant cell astrocytoma is usually normal.

Abdomen

  • Abdominal examination of patients with subependymal giant cell astrocytoma is usually normal.

Back

  • Back examination of patients with subependymal giant cell astrocytoma is usually normal.

Genitourinary

  • Genitourinary examination of patients with subependymal giant cell astrocytoma is usually normal.

Neuromuscular

Extremities

  • Extremities examination of patients with subependymal giant cell astrocytoma is usually normal.
References

References

  1. ↑ Sasongko, Teguh Haryo; Ismail, Nur Farrah Dila; Nik Abdul Malik, Nik Mohamad Ariff; Zabidi-Hussin, Z. A. M. H. (2015). “Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis”. Orphanet Journal of Rare Diseases. 10 (1). doi:10.1186/s13023-015-0317-7. ISSNΒ 1750-1172.
  2. ↑ Ouyang, Taohui; Zhang, Na; Benjamin, Thomas; Wang, Long; Jiao, Jiantong; Zhao, Yiqing; Chen, Jian (2014). “Subependymal giant cell astrocytoma: current concepts, management, and future directions”. Child’s Nervous System. 30 (4): 561–570. doi:10.1007/s00381-014-2383-x. ISSNΒ 0256-7040.
  3. ↑ Roth, Jonathan; Roach, E. Steve; Bartels, Ute; JΓ³ΕΊwiak, Sergiusz; Koenig, Mary Kay; Weiner, Howard L.; Franz, David N.; Wang, Henry Z. (2013). “Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis Complex Consensus Conference 2012”. Pediatric Neurology. 49 (6): 439–444. doi:10.1016/j.pediatrneurol.2013.08.017. ISSNΒ 0887-8994.
  4. ↑ Goh S, Butler W, Thiele EA (2004). “Subependymal giant cell tumors in tuberous sclerosis complex”. Neurology. 63 (8): 1457–61. doi:10.1212/01.wnl.0000142039.14522.1a. PMIDΒ 15505165.
  5. ↑ Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus Group (2013). “Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference”. Pediatr Neurol. 49 (4): 243–54. doi:10.1016/j.pediatrneurol.2013.08.001. PMCΒ 4080684. PMIDΒ 24053982.


Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ifeoma Odukwe, M.D. [2], Sujit Routray, M.D. [3]